Skip to main content

Table 3 Summary of placental transfer and mammary excretion of various angiotensin receptor blockers

From: Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats

Disposition site Drug Dose (mg/kg) Route Gestation or Lactation day Time after dose Maternal
Plasma conc. (PL)
Milk (MI) or Fetus (FE) conc. KP % (MI/PL or FE/PL) Reference
Fetus Losartan 135 P.O.
(Multiple)
6 ~ 15 88a (μg · hr/mL) [17]
15 ~ 20 194.8a (μg · hr/mL) 50.7a (μg · hr/mL) 26.0
Telmisartan 1 P.O. 12 4 43.56 (ng-eq/mL) 11.83 (ng-eq/g) 27.2 [18, 21]
12 8 34.47 (ng-eq/mL) 11.03 (ng-eq/g) 32.0
12 24 5.98 (ng-eq/mL) 7.98 (ng-eq/g) 133.4
12 48 3.65 (ng-eq/mL) 1.89 (ng-eq/g) 51.8
18 4 77.05 (ng-eq/mL) 13.72 (ng-eq/g) 17.8
18 24 19.73 (ng-eq/mL) 45.27 (ng-eq/g) 229.4
18 48 9.01 (ng-eq/mL) 17.65 (ng-eq/g) 195.9
Olmesartan P.O. 18 >100 [19]
Valsartan 600 18 1 7 ~ 9 (μg-eq/g) 4 ~ 5 (μg-eq/g) 56.0 [20]
18 24 NDb 3 ~ 4 (μg-eq/g)
Milk Losartan 135 P.O.
(Multiple)
7 3.86 (μg/mL) 1.16 (μg/mL) 30.1 [17]
14 3.00 (μg/mL) 1.96 (μg/mL) 65.3
21 3.14 (μg/mL) 1.71 (μg/mL) 54.5
Telmisartan 1 P.O. 0.5 23.77 (ng-eq/mL) 3.32 (ng-eq/mL) 14.0 [18, 21]
2 31.04 (ng-eq/mL) 30.6 (ng-eq/mL) 98.6
4 34.84 (ng-eq/mL) 54.24 (ng-eq/mL) 155.7
8 36.12 (ng-eq/mL) 66.08 (ng-eq/mL) 182.9
24 9.3 (ng-eq/mL) 13.52 (ng-eq/mL) 145.4
48 4.06 (ng-eq/mL) 6.79 (ng-eq/mL) 167.2
Olmesartan P.O. 72 25.0 [19]
Valsartan 600 NDb [20]
  1. aRepresented as AUC (μg · hr/mL), b ND: Not Detected